Warning letter · FDA Warning Letters

Biorica International Corp.: FDA Warning Letter 659194 (Aug 4, 2023)

Agency action: Aug 4, 2023Record ID: fda_warning_-48bdfcfb6279940c
View official source ↗

What happened

Original notice title

Biorica International Corp. MARCS-CMS 659194, August 04, 2023

From the archived source record

Most will do more harm than good and actually increase plaque build-up in your arteries and cause fatty liver disease…You can help your body heal itself. A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). Accordingly, Plaquex® Oral Dietary Supplement fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)]. This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
FDA closeout listed
Source checked
Jul 16, 2026
Record revision
5e192736ae0c

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
Plaquex® Oral Dietary Supplement
Company
Biorica International Corp.
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.